| Name | Title | Contact Details |
|---|
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Valiant Living is a company that offers comprehensive outpatient treatment and recovery services for men and their families, as well as enhanced recovery living environments for men who need a productive transition period after primary treatment.
Autism Family Center fulfills a critical need for a coordinated, multidisciplinary approach to treating Autistic Disorder by providing a full range of services including Applied Behavior Analysis (ABA). Because we view families as an integrated system and believe that the health of every member is vital for each member to thrive, Autism Family Center provides support services for the entire family. Our process is designed to ensure maximum learning, unity and happiness.
The RNS® System is an award-winning technology developed and manufactured in Silicon Valley that has been recognized for its innovation. Similar to a pacemaker that monitors and responds to heart rhythms, the RNS System is the world`s first and only medical device that can monitor and respond to brain activity. NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. The company`s initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.In addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.
Modern Health is the comprehensive mental health and wellness platform that combines the WHO well-being assessment, self-service wellness kits, a global network of certified coaches, and licensed therapists available in 35 languages all available in a single app. Modern Health empowers employers to lead the charge in acknowledging that mental health is just as important as physical health, destigmatizing the conversation, and increasing accessibility of mental health services for all. Founded in 2017, Modern Health incorporates evidence-based psychology principles and seamless technology to serve the needs of companies globally. Headquartered in San Francisco, Modern Health has raised more than $172 million from Founders Fund, Battery Ventures, Felicis Ventures, Kleiner Perkins, Afore Capital, MGV, Frederic Kerrest (co-founder of Okta), and 01 Advisors.